EAGLE BIOSCIENCES, INC

EAGLE BIOSCIENCES, INC specializes in the research, development, and manufacturing of high-complexity in vitro diagnostic reagents and assays for clinical and research applications. Their core capabilities include immunoassay design, enzymatic detection systems, and precision bioconjugation technologies, with a focus on analyte-specific reagents used in clinical laboratories. The company demonstrates technical expertise in assay validation, regulatory-compliant production processes, and quality systems aligned with CLIA, CAP, and ISO 13485 standards. Key differentiators include proprietary buffer formulations, stable lyophilized reagent platforms, and custom assay development for niche diagnostic markets, enabling reliable performance under varied laboratory conditions. Award history is not available to infer specific agency engagements, and no federal contract data is present to identify recurring government clients or mission-critical programs. Consequently, no definitive patterns of agency relationships can be established from the provided information. The company operates within the medical device and diagnostic manufacturing sector, primarily aligned with NAICS 334516, which encompasses in vitro diagnostic substance manufacturing. In practice, this means the development of reagents for clinical chemistry, immunoassays, and infectious disease testing, serving hospital labs, reference laboratories, and diagnostic instrument manufacturers. Their market positioning centers on high-purity, low-batch-variation reagents designed for integration into automated clinical platforms. EAGLE BIOSCIENCES, INC is a small business structured as a 2L entity, headquartered in Amherst, New Hampshire. The company holds no active government certifications such as 8(a), HUBZone, or WOSB. Its geographic footprint is limited to its primary manufacturing and R&D facility in New Hampshire, with no indication of federal contracting presence or participation in government procurement programs based on available data.